Q3 EPS Forecast for Axsome Therapeutics Reduced by Analyst

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Stock analysts at Zacks Research lowered their Q3 2026 earnings estimates for Axsome Therapeutics in a research report issued on Thursday, January 16th. Zacks Research analyst R. Department now forecasts that the company will post earnings per share of $0.04 for the quarter, down from their previous forecast of $0.11. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($4.61) per share.

Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.34) EPS for the quarter, topping the consensus estimate of ($1.38) by $0.04. Axsome Therapeutics had a negative net margin of 91.87% and a negative return on equity of 158.36%. The firm had revenue of $104.76 million for the quarter, compared to analyst estimates of $98.71 million. During the same period in the prior year, the business posted ($1.32) EPS.

Several other research firms also recently issued reports on AXSM. Truist Financial boosted their price objective on Axsome Therapeutics from $150.00 to $180.00 and gave the company a “buy” rating in a report on Monday, January 13th. Needham & Company LLC reissued a “buy” rating and set a $133.00 price target on shares of Axsome Therapeutics in a research report on Monday, January 13th. Robert W. Baird raised their price objective on shares of Axsome Therapeutics from $112.00 to $116.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. StockNews.com raised shares of Axsome Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. Finally, Mizuho decreased their price target on shares of Axsome Therapeutics from $124.00 to $122.00 and set an “outperform” rating for the company in a research report on Tuesday, December 31st. One equities research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $130.69.

Axsome Therapeutics Stock Down 1.9 %

NASDAQ:AXSM opened at $91.93 on Monday. Axsome Therapeutics has a 52 week low of $64.11 and a 52 week high of $105.00. The stock’s fifty day moving average is $92.29 and its two-hundred day moving average is $89.61. The stock has a market capitalization of $4.45 billion, a price-to-earnings ratio of -14.08 and a beta of 1.04. The company has a quick ratio of 2.37, a current ratio of 2.44 and a debt-to-equity ratio of 1.97.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Axsome Therapeutics in the 2nd quarter valued at about $27,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Axsome Therapeutics during the second quarter worth approximately $47,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Axsome Therapeutics by 22.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,736 shares of the company’s stock valued at $156,000 after acquiring an additional 318 shares during the period. Moors & Cabot Inc. purchased a new stake in Axsome Therapeutics in the 3rd quarter valued at $200,000. Finally, Whalen Wealth Management Inc. acquired a new stake in Axsome Therapeutics during the 3rd quarter worth $236,000. 81.49% of the stock is owned by hedge funds and other institutional investors.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.